CA2515289A1 - Weak base salts - Google Patents

Weak base salts Download PDF

Info

Publication number
CA2515289A1
CA2515289A1 CA002515289A CA2515289A CA2515289A1 CA 2515289 A1 CA2515289 A1 CA 2515289A1 CA 002515289 A CA002515289 A CA 002515289A CA 2515289 A CA2515289 A CA 2515289A CA 2515289 A1 CA2515289 A1 CA 2515289A1
Authority
CA
Canada
Prior art keywords
salt
pharmaceutical composition
carbon atoms
less
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002515289A
Other languages
English (en)
French (fr)
Inventor
Samuel H. Yalkowsky
Tapan Sanghvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/402,347 external-priority patent/US7022712B2/en
Application filed by Individual filed Critical Individual
Publication of CA2515289A1 publication Critical patent/CA2515289A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002515289A 2003-03-12 2004-03-12 Weak base salts Abandoned CA2515289A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45403503P 2003-03-12 2003-03-12
US60/454,035 2003-03-12
US45451403P 2003-03-13 2003-03-13
US60/454,514 2003-03-13
US10/402,347 US7022712B2 (en) 2002-03-26 2003-03-26 Solubilization of weak bases
US10/402,347 2003-03-26
PCT/US2004/007786 WO2004081006A1 (en) 2003-03-12 2004-03-12 Weak base salts

Publications (1)

Publication Number Publication Date
CA2515289A1 true CA2515289A1 (en) 2004-09-23

Family

ID=32995897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002515289A Abandoned CA2515289A1 (en) 2003-03-12 2004-03-12 Weak base salts

Country Status (6)

Country Link
EP (1) EP1606290A1 (https=)
JP (1) JP2006519852A (https=)
AU (1) AU2004220053A1 (https=)
CA (1) CA2515289A1 (https=)
MX (1) MXPA05009564A (https=)
WO (1) WO2004081006A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102216306B (zh) * 2008-11-19 2014-12-24 赛福伦公司 吲唑并[5,4-a]吡咯并[3,4-c]咔唑化合物的新形式
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1195180A (en) * 1967-05-05 1970-06-17 Du Pont Use of Alkyl 2-Benzimidazole-Carbamate Salts a Fungicides
CA962588A (en) * 1972-05-17 1975-02-11 Her Majesty In Right Of Canada As Represented By The Minister Of The Env Ironment, And Canadian Patents And Development Limited Method, apparatus, and fungicides for the treatment of trees subject to dutch elm disease and other fungus diseases
JPS5459338A (en) * 1977-10-20 1979-05-12 Takeda Chem Ind Ltd Remedy for dermatomycosis
HU199431B (en) * 1985-02-04 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing carbendazim salts, and fungicide comprising such carbendazim salt as active ingredient
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer

Also Published As

Publication number Publication date
JP2006519852A (ja) 2006-08-31
EP1606290A1 (en) 2005-12-21
MXPA05009564A (es) 2005-11-17
AU2004220053A1 (en) 2004-09-23
WO2004081006A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
CA2515289A1 (en) Weak base salts
ES2946489T3 (es) Formas sólidas y formulaciones de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamida
ES2732360T3 (es) Forma cristalina del 4-[5-(piridin-4-il)-1H-1,2,4-triazol-3-il]piridin-2-carbonitrilo
JP7134294B2 (ja) 改善された特性を有するβ－グアニジノプロピオン酸の薬学的に許容される塩及びその使用
CA2943998C (en) Salt of 1-(2-deoxy-2-fluoro-4-thio-.beta.-d-arabinofuranosyl)cytosine
JP6370377B2 (ja) 非晶質形態のダサチニブの塩
JP2009542785A (ja) 短時間作用型ベンゾジアゼピンの塩およびそれらの多形形態
BR112016002770B1 (pt) Sal de hemissulfato de ácido 5,10-metileno-(6r)-tetra-hidrofólico, sua composição farmacêutica e seu uso
HU231013B1 (hu) Dasatinib sók
ES2975319T3 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
ES2716633T3 (es) Formas cristalinas de fosfato de cabozantinib e hidrocloruro de cabozantinib
US20070043070A1 (en) Weak base salts
PT2448945E (pt) Formas cristalinas de sais de prasugrel
Mannava et al. Solubility and permeability enhancement of BCS class IV drug ribociclib through cocrystallization
An et al. Exploring the differences in crystal structure landscapes and physicochemical properties of enrofloxacin through the number of-OH in coformers: A case study
Surov et al. Solubility/distribution thermodynamics and permeability of two anthelmintics in biologically relevant solvents
PL244577B1 (pl) Sole nimesulidu i sposób otrzymywania kryształów soli nimesulidu
US8530501B2 (en) Salts and crystalline forms of a factor Xa inhibitor
EP4169914A1 (en) Salt of compound and pharmaceutical composition containing salt
CN103841828B (zh) 德尼布林二盐酸盐
US10344041B2 (en) Polymorphic forms and co-crystals of a c-Met inhibitor
BR102021009918A2 (pt) Dispersão sólida do antibiótico rifampicina
Voronin et al. Trimorphism in riluzole salicylate: screening, crystal structures and solution thermodynamics
WO2026046946A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
HK40088128A (en) Salt of compound and pharmaceutical composition containing salt

Legal Events

Date Code Title Description
FZDE Discontinued